The brand for the Meals and Drug Administration is seen forward of a information convention on the Well being and Human Companies Headquarters in Washington, April 22, 2025.
Nathan Posner | Anadolu | Getty Photos
A key U.S. Meals and Drug Administration official who oversees vaccines and biotech remedies will step down from the company following a number of selections that raised considerations inside the business.
Vinay Prasad, director of the Heart for Biologics Analysis and Analysis, will depart the FDA on the finish of April, an company spokesperson confirmed on Friday. It’s his second departure from the place: He briefly left the submit in July following backlash over his regulatory selections, and returned solely two weeks later in August.
In a submit on X, FDA Commissioner Marty Makary mentioned the FDA will appoint a successor earlier than Prasad returns subsequent month to the College of California, San Francisco, the place he taught earlier than taking the FDA place final yr. Makary mentioned Prasad “acquired an amazing quantity completed” throughout his tenure on the company.
Prasad’s choice to step down comes after mounting criticism of the FDA inside the biotech and pharmaceutical industries and amongst former well being officers. Previously yr, the company has denied or discouraged the approval functions of no less than eight medication, in response to RTW Investments, after taking challenge with knowledge the businesses used to help their functions. The FDA initially refused to assessment Moderna’s flu shot, however later reversed course.
All of these corporations accused the FDA of reversing earlier steerage on the proof they might use to help their functions, sparking business criticism that an unreliable regulatory course of might stifle the event of medicine for hard-to-treat illnesses.
A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the problem known as the reversals the worst type of regulatory uncertainty as a result of corporations say they’re being informed one factor after which expertise one other.
In a press release earlier Friday, an FDA spokesperson mentioned there was “no regulatory uncertainty,” including the company “makes selections primarily based on the proof, however doesn’t make assurances about outcomes.” The spokesperson mentioned the FDA is “conducting rigorous, unbiased evaluations and never rubber-stamping approvals.”
The newest controversy arose after the FDA discouraged UniQure from making use of for expedited approval of its experimental remedy for Huntington’s illness.
The company, which underwent employees cuts and an overhaul beneath Well being and Human Companies Secretary Robert F. Kennedy Jr., has confronted broader backlash for its drug and vaccine approval course of. Critics have anxious that the company might stifle the event of recent remedies and threat the security of sufferers.
Criticism of Prasad had been rising and reached a fever pitch when the FDA’s Makary, in an interview with CNBC’s Becky Fast final week, appeared to criticize UniQure’s gene remedy for Huntington’s illness. Makary did not title UniQure however described its remedy.
Requires a shakeup grew even louder at a CNBC Cures occasion this week.
The Wall Avenue Journal first reported Prasad’s departure.
